

June 7, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting

TOKYO, Japan, June 7, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) announced on June 6, 2016 (EST) the presentation of data in two poster presentations for (i) the mechanistic rationale for combining oral rigosertib with azacitidine and (ii) the background and rationale for the IV rigosertib trial, at the 2016 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held from June 3-7, 2016 in Chicago, Illinois.

For the oral rigosertib/azacitidine poster presentation, investigators evaluated and confirmed the synergistic activity of the oral rigosertib/azacitidine combination in myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) cell lines and patients’ bone marrow, studies in which a novel effect on epigenetics was also revealed. Onconova is currently evaluating the oral rigosertib and azacitidine combination in a fully enrolled, multi-center Phase 2 trial (NCT01926587). Onconova plans to share these results with regulatory agencies, and an update on this study will be presented at the European Hematology Association meeting to be held later this month.

In the second poster presentation, the novel design and eligibility criteria employed in Onconova’s global randomized Phase 3 INSPIRE trial for IV rigosertib in the 2nd-line MDS patient setting were outlined by the study’s investigators. The study is currently enrolling patients in the U.S., Europe and Japan at more than 50 sites.

SymBio obtained the licensing rights for rigosertib in July, 2011 and retains the development rights for Japan and Korea.

For more details in this press release, please visit Onconova’s homepage at <http://investor.onconova.com/releases.cfm>

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Myelodysplastic Syndromes (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and higher-risk MDS.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, USA, President: Mr. Fuminori Yoshida).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.